Literature DB >> 2374713

Formation of a DNA monofunctional cis-platinum adduct cross-linking the intercalating drug N-methyl-2,7-diazapyrenium.

J M Malinge1, M Sip, A J Blacker, J M Lehn, M Leng.   

Abstract

Our purpose was to better understand the mutual influence of cis-diamminedichloroplatinum (II) (cis-DDP) and intercalating drugs in their interactions with DNA. The present study deals with the intercalating drug N-methyl-2,7-diazapyrenium (MDAP). Two sets of experiments have been performed. In one set, the reaction between cis-DDP and nucleic acid was carried out in the presence of MDAP. The main adduct is a guanine residue chelated by platinum to a MDAP residue. It has the same spectroscopic properties as the synthesized compound cis-[Pt (NH3)2 (N7-d-guanosine) (N7-MDAP)] , the structure of which has been determined by 1H NMR. This adduct was only formed with double-stranded nucleic acids which reveals the importance of DNA matrix in orienting favorably the reactants. In the second set of experiments, the triamine complex cis-[Pt(NH3)2 (MDAP)CI]++ was reacted with the nucleic acids. At molar ratios drug over nucleotide residue equal or less than 0.10, all the added triamine complexes bind by covalent coordination to double-stranded nucleic acids. With natural DNA, the major adduct is cis-[Pt(NH3)2(d-guanosine) (MDAP)] . Thus the same adduct is formed on one hand in the reaction between DNA, MDAP and cis-DDP and on the other hand in the reaction between the triamine complex and DNA. The triamine complex offers the possibility to study the biological role of the new adduct.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2374713      PMCID: PMC331090          DOI: 10.1093/nar/18.13.3887

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  20 in total

Review 1.  The role of antitumor antibiotics in current oncologic practice.

Authors:  H L Davis; D D von Hoff; J E Henney; M Rozencweig
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  Combination chemotherapy with cis-dichlorodiammineplatinum(II) in disseminated testicular cancer.

Authors:  L H Einhorn
Journal:  Cancer Treat Rep       Date:  1979 Sep-Oct

3.  Ethidium bromide alters the binding mode of cis-diamminedichloroplatinum(II) to pBR322 DNA.

Authors:  C M Merkel; S J Lippard
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1983

Review 4.  Physico-chemical probes of intercalation.

Authors:  G Dougherty; J R Pilbrow
Journal:  Int J Biochem       Date:  1984

5.  Ethidium bromide changes the nuclease-sensitive DNA binding sites of the antitumor drug cis-diamminedichloroplatinum(II).

Authors:  T D Tullius; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

6.  Specific platinum chelation by the guanines of the deoxyhexanucleotide d(T-G-G-C-C-A) upon reaction with cis-[Pt(NH3)2(H2O)2](NO3)2.

Authors:  J P Girault; J C Chottard; E R Guittet; J Y Lallemand; T Huynh-Dinh; J Igolen
Journal:  Biochem Biophys Res Commun       Date:  1982-12-31       Impact factor: 3.575

7.  Alteration and activation of sequence-specific cleavage of DNA by bleomycin in the presence of the antitumor drug cis-diamminedichloroplatinum(II).

Authors:  P K Mascharak; Y Sugiura; J Kuwahara; T Suzuki; S J Lippard
Journal:  Proc Natl Acad Sci U S A       Date:  1983-11       Impact factor: 11.205

8.  Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck.

Authors:  D J Perry; M D Weltz; A W Brown; R L Henderson; W J Neglia; J L Berenberg
Journal:  Cancer       Date:  1982-12-01       Impact factor: 6.860

9.  Modulation of platinum antitumor drug binding to DNA by linked and free intercalators.

Authors:  B E Bowler; S J Lippard
Journal:  Biochemistry       Date:  1986-05-20       Impact factor: 3.162

10.  Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.

Authors:  A M Fichtinger-Schepman; J L van der Veer; J H den Hartog; P H Lohman; J Reedijk
Journal:  Biochemistry       Date:  1985-01-29       Impact factor: 3.162

View more
  5 in total

1.  Rearrangement of interstrand cross-links into intrastrand cross-links in cis-diamminedichloroplatinum(II)-modified DNA.

Authors:  C Pérez; M Leng; J M Malinge
Journal:  Nucleic Acids Res       Date:  1997-02-15       Impact factor: 16.971

2.  Possible catalytic activity of DNA in the reaction between the antitumor drug cis-diamminedichloroplatinum(II) and the intercalator N-methyl-2,7-diazapyrenium.

Authors:  F Gaucheron; J M Malinge; A J Blacker; J M Lehn; M Leng
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

3.  Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA.

Authors:  D Payet; F Gaucheron; M Sip; M Leng
Journal:  Nucleic Acids Res       Date:  1993-12-25       Impact factor: 16.971

4.  Lability of monofunctional cis-platinum adducts: role of DNA double helix.

Authors:  M F Anin; F Gaucheron; M Leng
Journal:  Nucleic Acids Res       Date:  1992-09-25       Impact factor: 16.971

5.  Monofunctional and higher-valent platinum anticancer agents.

Authors:  Timothy C Johnstone; Justin J Wilson; Stephen J Lippard
Journal:  Inorg Chem       Date:  2013-06-05       Impact factor: 5.165

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.